Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company focused on central nervous system (CNS) and immunology treatments, announced that a poster on Tonmya™ (cyclobenzaprine HCl sublingual tablets), investigated as TNX-102 SL, will be presented at the 2026 PainConnect Annual Meeting hosted by the American Academy of Pain Medicine (AAPM). The meeting is scheduled for March 5-8, 2026, in Salt Lake City, Utah, where the company will share data related to its investigational therapy as part of the scientific program.
Tonmya, the company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. The presentation at the AAPM meeting underscores the importance of this therapy in addressing a condition with high unmet medical need. Fibromyalgia affects millions of patients worldwide, and the approval of Tonmya provides a new option for those who have not responded to existing treatments.
Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. The company is also maximizing the science behind Tonmya in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, Tonix’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease.
Beyond CNS, the company is advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs highlight Tonix’s broader commitment to addressing serious medical conditions.
The presentation at the AAPM PainConnect Annual Meeting is a significant opportunity for Tonix to engage with pain management specialists and showcase the clinical data supporting Tonmya. The meeting attracts leading experts in pain medicine, and the data presented could influence clinical practice and future research directions.
For more information about Tonix Pharmaceuticals and its pipeline, visit the company’s newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/kwTPM.
